Gene therapy specialist, Targeted Genetics (Seattle, WA) is to buy another gene therapy company, Genovo (Philadelphia, PA) in a stock swap valued at nearly $90 million. The acquisition brings Targeted a new partner, Biogen (Cambridge, MA), which has paid Genovo nearly $40 million since 1995 for marketing rights to liver- and lung-related genetic therapies. That deal has been extended and is now reportedly worth a potential $125 million to the Seattle company.
Rights and permissions
About this article
Cite this article
Hodgson, J. Gene therapy buy. Nat Biotechnol 18, 911 (2000). https://doi.org/10.1038/79318
Issue Date:
DOI: https://doi.org/10.1038/79318